Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 1;15(1):189.
doi: 10.1038/s41408-025-01393-8.

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

Eric Jurgens  1 , Tala Shekarkhand  1 , Colin Rueda  1 , David Nemirovsky  2 , Andriy Derkach  2 , Ross S Firestone  1 , Kevin Miller  1 , Bruno Almeida Costa  1   3 , Sridevi Rajeeve  1 , Alexander M Lesokhin  1 , Neha Korde  1 , Carlyn R Tan  1 , Hamza Hashmi  1 , Hani Hassoun  1 , Kylee Maclachlan  1 , Urvi A Shah  1 , Malin Hultcrantz  1 , Issam Hamadeh  4 , Sergio A Giralt  5 , Gunjan L Shah  5 , Heather J Landau  5 , Michael Scordo  5 , Saad Z Usmani  1   5 , Sham Mailankody  1 , Zainab Shahid  6
Affiliations

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

Eric Jurgens et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Incidence and Patterns of CMV Reactivation.
A Schematic of patients included in study as well CMV detection and CMV reactivation analyses. B Heatmap of serum CMV DNA PCR during the first 100 days of BsAb treatment. Individual patients are depicted on the left Y-axis and grouped by BsAb depicted on the right Y-axis. Each box indicates an individual serum CMV DNA PCR test. Shading within the box corresponds to CMV DNV PCR log10 result. C Cumulative incidence of CMV detection and D reactivation during BsAb therapy. CMV Cytomegalovirus, PCR polymerase chain reaction, BsAb bispecific antibody.
See this image and copyright information in PMC

References

    1. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. 10.1056/NEJMoa2203478. - DOI - PMC - PubMed
    1. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetisMM-3 trial results. Nat Med. 2023. 10.1038/s41591-023-02528-9. - PMC - PubMed
    1. Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, et al. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232–44. 10.1056/NEJMoa2204591. - DOI - PubMed
    1. Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, et al. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14:88. 10.1038/s41408-024-01043-5. - DOI - PMC - PubMed
    1. Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7:5898–903. 10.1182/bloodadvances.2023010539. - DOI - PMC - PubMed

LinkOut - more resources